IDEAYA Biosciences, Inc., a leader in precision oncology, has unveiled the nomination of its development candidate, IDE892, a prospective leading MTA-cooperative PRMT5 inhibitor.
“We are thrilled to broaden our precision oncology portfolio with the nomination of our 7th development candidate, IDE892, a promising MTA-cooperative PRMT5 inhibitor,” remarked Yujiro S. Hata, president and CEO of IDEAYA Biosciences. “This advances our strategic goal of integrating the PRMT5 and MAT2A pathways, aiming for heightened efficacy in MTAP-deletion solid tumors through a well-thought-out combined therapy,” Hata emphasized.
“Through meticulous structure-based design and optimization, we have reached our product profile goals for the PRMT5 initiative with IDE892, which includes significant potency, selective action, and synergistic combination potential with the MAT2A inhibitor IDE397,” explained Michael White, Ph.D., chief scientific officer at IDEAYA Biosciences.
Derived from IDEAYA’s advanced iterative ligand design and refinement process, IDE892 stands out as a highly potent and specialized MTA-cooperative PRMT5 inhibitor, showcasing potential as a best-in-class candidate with favorable drug-like qualities. IDE892 has shown remarkably selective antiproliferative effects in MTAP-deleted tumor models and has led to durable complete responses when paired with MAT2A inhibitor IDE397 in rigorous preclinical studies involving MTAP-deletion models. Presently, IND-enabling research for IDE892 continues to lay the groundwork for submitting an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) by mid-2025, contingent upon successful preclinical and enabling studies.
IDEAYA Biosciences is devoted to pioneering precision medicine therapies, focusing on discovering and developing targeted treatments for patients identified through molecular diagnostics.